RADX
NASDAQRadiopharm Theranostics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.05-0.03 (-2.78%)
02:30 PM03:15 PM
News · 26 weeks50-20%
2026-04-192026-10-11
Mix3690d
- SEC Filings24(67%)
- Other11(31%)
- Offering1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage radiopharmaceutical company, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA or the Agency) regarding RAD101, the Company's investigational radiopharmaceutical imaging agent for the detection of brain metastases. RAD101 is the Company's no
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 20-F filed by Radiopharm Theranostics Limited20-F - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form EFFECT filed by Radiopharm Theranostics LimitedEFFECT - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 424B3 filed by Radiopharm Theranostics Limited424B3 - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingRAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that positive data from an interim analysis of the Company’s Phase 2b imaging clinical
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form F-3 filed by Radiopharm Theranostics LimitedF-3 - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaPositive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced positive data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in health
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsSYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01. RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, des
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAdvancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic a
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- PRRadiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain MetastasesRAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U.S. FDA scheduled for October 1st , 2026; on track to be Phase 3 ready by year-end 2026 SYDNEY and MALVERN, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has scheduled an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for October 1st , 2026, to align
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
- SECSEC Form 6-K filed by Radiopharm Theranostics Limited6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
RADX FAQ
5 questionsWhere does RADX stock trade?
Radiopharm Theranostics Limited (RADX) is listed on NASDAQ.What sector and industry is RADX in?
Radiopharm Theranostics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about RADX?
Radiopharm Theranostics Limited has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $600.00 price target on 2026-06-04. Recent price targets range from $600.00 to $1500.00.What companies are similar to RADX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RADX side-by-side with any of them on Quantisnow.How can I track RADX on Quantisnow?
Quantisnow aggregates Radiopharm Theranostics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RADX to receive live email and push alerts on every new disclosure.